Yervoy
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
Sales of the CAR T-cell therapy continue to grow helped by BMS's expansion of its cell manufacturing facilities.
Upfront Amtagvi-Keytruda Shows Promise in Checkpoint Inhibitor-Naive Melanoma, but Questions Remain
Premium
Iovance's autologous TIL therapy plus Merck's PD-1 drug led to encouraging responses in a Phase II trial, but some oncologists challenged the Phase III design.
BMS Seeking EU Approval of First-Line Opdivo, Yervoy in MSI-High, dMMR Colorectal Cancer
The drugmaker also filed for US approval of a subcutaneous formulation of Opdivo, which would apply to all solid tumor indications.
Apr 25, 2024